214 related articles for article (PubMed ID: 34629712)
1. Radioembolization of Secondary Hepatic Malignancies.
Manchec B; Kokabi N; Narayanan G; Niekamp A; Peña C; Powell A; Schiro B; Gandhi R
Semin Intervent Radiol; 2021 Oct; 38(4):445-452. PubMed ID: 34629712
[TBL] [Abstract][Full Text] [Related]
2. Current status of transarterial radioembolization.
Mahnken AH
World J Radiol; 2016 May; 8(5):449-59. PubMed ID: 27247711
[TBL] [Abstract][Full Text] [Related]
3. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment albumin may aid in patient selection for intrahepatic Y-90 microsphere transarterial radioembolization (TARE) for malignancies of the liver.
Orwat KP; Beckham TH; Cooper SL; Ashenafi MS; Anderson MB; Guimaraes M; Yamada R; Marshall DT
J Gastrointest Oncol; 2017 Dec; 8(6):1072-1078. PubMed ID: 29299369
[TBL] [Abstract][Full Text] [Related]
5. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver Metastases.
Tomozawa Y; Jahangiri Y; Pathak P; Kolbeck KJ; Schenning RC; Kaufman JA; Farsad K
J Vasc Interv Radiol; 2018 Jun; 29(6):858-865. PubMed ID: 29724520
[TBL] [Abstract][Full Text] [Related]
7. The use of neoadjuvant lobar radioembolization prior to major hepatic resection for malignancy results in a low rate of post hepatectomy liver failure.
Ahmed A; Stauffer JA; LeGout JD; Burns J; Croome K; Paz-Fumagalli R; Frey G; Toskich B
J Gastrointest Oncol; 2021 Apr; 12(2):751-761. PubMed ID: 34012663
[TBL] [Abstract][Full Text] [Related]
8. Transarterial radioembolization with yttrium-90 of unresectable primary hepatic malignancy in children.
Aguado A; Ristagno R; Towbin AJ; Gupta A; Haberle S; Qi Z; Patel MN; Kukreja KU; Tiao GM; Geller JI
Pediatr Blood Cancer; 2019 Jul; 66(7):e27510. PubMed ID: 30406959
[TBL] [Abstract][Full Text] [Related]
9. Quality of Life and Cost Considerations: Y-90 Radioembolization.
Williams SJ; Rilling WS; White SB
Semin Intervent Radiol; 2021 Oct; 38(4):482-487. PubMed ID: 34629718
[No Abstract] [Full Text] [Related]
10. Transarterial radioembolization with Iodine-131-Lipiodol for hepatic metastases from gastrointestinal malignancies - Experience in tertiary care oncology center in India.
Bhargavi V; Subbanna I; Kallur KG; Patel A; Swamy S; Patil S
South Asian J Cancer; 2019; 8(1):31-34. PubMed ID: 30766849
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Trans-Arterial Yttrium-90 Radioembolization in Patients with Unresectable Liver-Dominant Metastatic or Primary Hepatic Soft Tissue Sarcomas.
Testa S; Bui NQ; Wang DS; Louie JD; Sze DY; Ganjoo KN
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053486
[TBL] [Abstract][Full Text] [Related]
12. Ytrrium-90 transarterial radioembolization in patients with gastrointestinal malignancies.
Viñal D; Minaya-Bravo A; Prieto I; Feliu J; Rodriguez-Salas N
Clin Transl Oncol; 2022 May; 24(5):796-808. PubMed ID: 35013882
[TBL] [Abstract][Full Text] [Related]
13. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma.
Kallini JR; Gabr A; Salem R; Lewandowski RJ
Adv Ther; 2016 May; 33(5):699-714. PubMed ID: 27039186
[TBL] [Abstract][Full Text] [Related]
14. Transarterial Radioembolization Agents: a Review of the Radionuclide Agents and the Carriers.
Alrfooh A; Patel A; Laroia S
Nucl Med Mol Imaging; 2021 Aug; 55(4):162-172. PubMed ID: 34422126
[TBL] [Abstract][Full Text] [Related]
15. Current role of transarterial chemoembolization and radioembolization in the treatment of metastatic colorectal cancer.
Bester L; Meteling B; Boshell D; Saxena A; Morris DL
Hepat Oncol; 2014 Apr; 1(2):215-228. PubMed ID: 30190956
[TBL] [Abstract][Full Text] [Related]
16. Apparent diffusion coefficients (ADC) in response assessment of transarterial radioembolization (TARE) for liver metastases of neuroendocrine tumors (NET): a feasibility study.
Katharina Ingenerf M; Karim H; Fink N; Ilhan H; Ricke J; Treitl KM; Schmid-Tannwald C
Acta Radiol; 2022 Jul; 63(7):877-888. PubMed ID: 34225464
[TBL] [Abstract][Full Text] [Related]
17. Repeated radioembolization in advanced liver cancer.
Masthoff M; Schindler P; Harders F; Heindel W; Wilms C; Schmidt HH; Pascher A; Stegger L; Rahbar K; Wildgruber M; Köhler M
Ann Transl Med; 2020 Sep; 8(17):1055. PubMed ID: 33145274
[TBL] [Abstract][Full Text] [Related]
18. Metastatic disease to the liver: Locoregional therapy strategies and outcomes.
Zane KE; Cloyd JM; Mumtaz KS; Wadhwa V; Makary MS
World J Clin Oncol; 2021 Sep; 12(9):725-745. PubMed ID: 34631439
[TBL] [Abstract][Full Text] [Related]
19. Chronic Hepatotoxicity in Patients with Metastatic Neuroendocrine Tumor: Transarterial Chemoembolization versus Transarterial Radioembolization.
Currie BM; Nadolski G; Mondschein J; Dagli M; Sudheendra D; Stavropoulos SW; Soulen MC
J Vasc Interv Radiol; 2020 Oct; 31(10):1627-1635. PubMed ID: 33004146
[TBL] [Abstract][Full Text] [Related]
20. Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT).
Helmberger T; Golfieri R; Pech M; Pfammatter T; Arnold D; Cianni R; Maleux G; Munneke G; Pellerin O; Peynircioglu B; Sangro B; Schaefer N; de Jong N; Bilbao JI; ;
Cardiovasc Intervent Radiol; 2021 Jan; 44(1):21-35. PubMed ID: 32959085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
